Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …

Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates
and insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …